报价延迟最少15分钟:2026/04/21 18:57 EDT
盘后时段
|
||||
|
93.33 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
93.33
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.47/-0.33
|
|
企业价值
6.09B
|
| 资产负债 |
|
每股账面净值
5.22
|
| 现金流量 |
|
现金流量率
0.01
|
| 损益表 |
|
收益
521.31M
|
|
每股收益
2.40
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli. |
